Literature DB >> 17573534

Cellular prion protein regulates beta-secretase cleavage of the Alzheimer's amyloid precursor protein.

Edward T Parkin1, Nicole T Watt, Ishrut Hussain, Elizabeth A Eckman, Christopher B Eckman, Jean C Manson, Herbert N Baybutt, Anthony J Turner, Nigel M Hooper.   

Abstract

Proteolytic processing of the amyloid precursor protein (APP) by beta-secretase, beta-site APP cleaving enzyme (BACE1), is the initial step in the production of the amyloid beta (Abeta) peptide, which is involved in the pathogenesis of Alzheimer's disease. The normal cellular function of the prion protein (PrP(C)), the causative agent of the transmissible spongiform encephalopathies such as Creutzfeldt-Jakob disease in humans, remains enigmatic. Because both APP and PrP(C) are subject to proteolytic processing by the same zinc metalloproteases, we tested the involvement of PrP(C) in the proteolytic processing of APP. Cellular overexpression of PrP(C) inhibited the beta-secretase cleavage of APP and reduced Abeta formation. Conversely, depletion of PrP(C) in mouse N2a cells by siRNA led to an increase in Abeta peptides secreted into the medium. In the brains of PrP knockout mice and in the brains from two strains of scrapie-infected mice, Abeta levels were significantly increased. Two mutants of PrP, PG14 and A116V, that are associated with familial human prion diseases failed to inhibit the beta-secretase cleavage of APP. Using constructs of PrP, we show that this regulatory effect of PrP(C) on the beta-secretase cleavage of APP required the localization of PrP(C) to cholesterol-rich lipid rafts and was mediated by the N-terminal polybasic region of PrP(C) via interaction with glycosaminoglycans. In conclusion, this is a mechanism by which the cellular production of the neurotoxic Abeta is regulated by PrP(C) and may have implications for both Alzheimer's and prion diseases.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17573534      PMCID: PMC1904148          DOI: 10.1073/pnas.0609621104

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  38 in total

1.  Predicting susceptibility and incubation time of human-to-human transmission of vCJD.

Authors:  M T Bishop; P Hart; L Aitchison; H N Baybutt; C Plinston; V Thomson; N L Tuzi; M W Head; J W Ironside; R G Will; J C Manson
Journal:  Lancet Neurol       Date:  2006-05       Impact factor: 44.182

2.  The presenilin proteins are components of multiple membrane-bound complexes that have different biological activities.

Authors:  Yongjun Gu; Nobuo Sanjo; Fusheng Chen; Hiroshi Hasegawa; Agnes Petit; Xueying Ruan; Wenping Li; Cortney Shier; Toshitaka Kawarai; Gerold Schmitt-Ulms; David Westaway; Peter St George-Hyslop; Paul E Fraser
Journal:  J Biol Chem       Date:  2004-04-30       Impact factor: 5.157

3.  Concomitant Creutzfeldt-Jakob and Alzheimer diseases.

Authors:  J M Powers; Y Liu; L S Hair; R J Kascsack; L D Lewis; L A Levy
Journal:  Acta Neuropathol       Date:  1991       Impact factor: 17.088

Review 4.  ADAMs family members as amyloid precursor protein alpha-secretases.

Authors:  Tobias M J Allinson; Edward T Parkin; Anthony J Turner; Nigel M Hooper
Journal:  J Neurosci Res       Date:  2003-11-01       Impact factor: 4.164

5.  Prion protein codon 129 polymorphism and risk of Alzheimer disease.

Authors:  M Riemenschneider; N Klopp; W Xiang; S Wagenpfeil; C Vollmert; U Müller; H Förstl; T Illig; H Kretzschmar; A Kurz
Journal:  Neurology       Date:  2004-07-27       Impact factor: 9.910

6.  Specific inhibition of pathological prion protein accumulation by small interfering RNAs.

Authors:  Nathalie Daude; Mathieu Marella; Joelle Chabry
Journal:  J Cell Sci       Date:  2003-05-20       Impact factor: 5.285

7.  Dual mechanisms for shedding of the cellular prion protein.

Authors:  Edward T Parkin; Nicole T Watt; Anthony J Turner; Nigel M Hooper
Journal:  J Biol Chem       Date:  2004-01-07       Impact factor: 5.157

8.  The role of ADAM10 and ADAM17 in the ectodomain shedding of angiotensin converting enzyme and the amyloid precursor protein.

Authors:  Tobias M J Allinson; Edward T Parkin; Thomas P Condon; Sylva L U Schwager; Edward D Sturrock; Anthony J Turner; Nigel M Hooper
Journal:  Eur J Biochem       Date:  2004-06

Review 9.  Take five--BACE and the gamma-secretase quartet conduct Alzheimer's amyloid beta-peptide generation.

Authors:  Christian Haass
Journal:  EMBO J       Date:  2004-01-29       Impact factor: 11.598

10.  Heparan sulfate regulates amyloid precursor protein processing by BACE1, the Alzheimer's beta-secretase.

Authors:  Zoe Scholefield; Edwin A Yates; Gareth Wayne; Augustin Amour; William McDowell; Jeremy E Turnbull
Journal:  J Cell Biol       Date:  2003-10-06       Impact factor: 10.539

View more
  113 in total

Review 1.  Prion protein at the crossroads of physiology and disease.

Authors:  Emiliano Biasini; Jessie A Turnbaugh; Ursula Unterberger; David A Harris
Journal:  Trends Neurosci       Date:  2011-12-01       Impact factor: 13.837

2.  Role of alpha7 nicotinic acetylcholine receptor in calcium signaling induced by prion protein interaction with stress-inducible protein 1.

Authors:  Flavio H Beraldo; Camila P Arantes; Tiago G Santos; Nicolle G T Queiroz; Kirk Young; R Jane Rylett; Regina P Markus; Marco A M Prado; Vilma R Martins
Journal:  J Biol Chem       Date:  2010-09-13       Impact factor: 5.157

3.  Cellular prion protein promotes regeneration of adult muscle tissue.

Authors:  Roberto Stella; Maria Lina Massimino; Marco Sandri; M Catia Sorgato; Alessandro Bertoli
Journal:  Mol Cell Biol       Date:  2010-08-02       Impact factor: 4.272

4.  Memory impairment in transgenic Alzheimer mice requires cellular prion protein.

Authors:  David A Gimbel; Haakon B Nygaard; Erin E Coffey; Erik C Gunther; Juha Laurén; Zachary A Gimbel; Stephen M Strittmatter
Journal:  J Neurosci       Date:  2010-05-05       Impact factor: 6.167

Review 5.  An overview of APP processing enzymes and products.

Authors:  Vivian W Chow; Mark P Mattson; Philip C Wong; Marc Gleichmann
Journal:  Neuromolecular Med       Date:  2010-03       Impact factor: 3.843

6.  A nine amino acid domain is essential for mutant prion protein toxicity.

Authors:  Laura Westergard; Jessie A Turnbaugh; David A Harris
Journal:  J Neurosci       Date:  2011-09-28       Impact factor: 6.167

7.  Context dependent neuroprotective properties of prion protein (PrP).

Authors:  Andrew D Steele; Zhipeng Zhou; Walker S Jackson; Chunni Zhu; Pavan Auluck; Michael A Moskowitz; Marie-Francoise Chesselet; Susan Lindquist
Journal:  Prion       Date:  2009-10-16       Impact factor: 3.931

Review 8.  Cellular prion protein mediates the toxicity of beta-amyloid oligomers: implications for Alzheimer disease.

Authors:  Haakon B Nygaard; Stephen M Strittmatter
Journal:  Arch Neurol       Date:  2009-11

Review 9.  Beta-amyloid oligomers and cellular prion protein in Alzheimer's disease.

Authors:  Erik C Gunther; Stephen M Strittmatter
Journal:  J Mol Med (Berl)       Date:  2009-12-04       Impact factor: 4.599

Review 10.  Immunotherapy in prion disease.

Authors:  Yvonne Roettger; Yansheng Du; Michael Bacher; Inga Zerr; Richard Dodel; Jan-Philipp Bach
Journal:  Nat Rev Neurol       Date:  2012-12-18       Impact factor: 42.937

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.